zerohedge · 2026-08-19
Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company. The study met its primary endpoint by showing that the cancer vaccine, called in
Read the original at zerohedge ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。